Levodopa is the most efficacious agent for the treatment of motor features of Parkinson's disease but its chronic use is associated with the development of motor complications. Mounting evidence ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday. Shares of ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

it is currently offered to those who fail to respond to other treatments for Parkinson’s, including muscle-strengthening exercises as well as medications, such as levodopa, which reduce tremors ...

A recent study published in the journal Brain has revealed new insights into the neurological underpinnings of levodopa-induced dyskinesia, a common and debilitating complication of Parkinson’s ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced drug ...

In fluctuating Parkinson's disease (PD) patients, treatment of PD using the catechol-O-methyl transferase inhibitor entacapone with carbidopa/levodopa improves quality of life and activities of ...

A robust evaluation of the continuous dopaminergic stimulation hypothesis may require a longer acting levodopa preparation. In fluctuating Parkinson's disease (PD) patients, treatment of PD using ...